End of Compounded Semaglutide; 464M Teens Will Have Obesity; GLP-1 Scripts Skyrocket

By News Health
3 weeks Ago

(MedPage Today) — A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for tirzepatide (Mounjaro, Zepbound) passed in March. (U.S. News & World Report)
A patient-delivered lifestyle…

Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/115774

Author :

Publish date : 2025-05-27 19:34:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Early, Aggressive BP Lowering Tied to Better ICH Outcomes

Warning for Hepatitis C Care; MASLD Deaths to Double; EHR Frustration for IBD Docs

Your brain tracks your sleep debt – and now we may know how

Being a Black Man in Medical School Takes a Toll

Ukrainian Trauma Surgeon: 'Our Country Is Profoundly Exhausted'

Offsetting global fossil fuel stores by planting trees is impossible